国药系中药上市公司业绩双降,太极集团与中国中药面临“十四五”目标挑战

金融界
02 Apr

2024年,国药集团旗下的两家中药上市公司——太极集团和中国中药,均遭遇了营收与净利润的双重下滑。太极集团发布的年报显示,公司全年实现营业收入123.86亿元,同比下降20.72%;归属于上市公司股东的净利润仅为0.27亿元,同比下降96.76%。中国中药的年报同样不容乐观,其营业额为165.10亿元,同比下降8.9%;净利润为0.21亿元,同比下降98.5%。这一业绩表现,使得两家公司在实现“...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10